Skandinaviska Enskilda Banken AB publ Has $76.98 Million Holdings in Cencora, Inc. (NYSE:COR)

Skandinaviska Enskilda Banken AB publ increased its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 122.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 342,582 shares of the company's stock after buying an additional 188,660 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.18% of Cencora worth $76,982,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of COR. Hickory Asset Management Inc. acquired a new stake in Cencora in the 4th quarter worth $572,000. Sylvest Advisors LLC acquired a new stake in Cencora during the fourth quarter worth about $1,105,000. Insight Wealth Strategies LLC increased its stake in Cencora by 124.6% during the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock valued at $4,549,000 after acquiring an additional 11,232 shares during the period. Cerity Partners LLC increased its stake in Cencora by 10.1% during the third quarter. Cerity Partners LLC now owns 39,457 shares of the company's stock valued at $8,881,000 after acquiring an additional 3,610 shares during the period. Finally, Vontobel Holding Ltd. raised its holdings in Cencora by 46.9% in the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after acquiring an additional 1,995 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 4,970 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the transaction, the chief executive officer now owns 51,070 shares in the company, valued at approximately $13,022,850. This trade represents a 8.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,648 shares of company stock worth $3,382,462 in the last three months. Insiders own 10.80% of the company's stock.

Remove Ads

Cencora Trading Up 1.1 %

Shares of COR traded up $2.91 during trading hours on Monday, hitting $260.98. 1,238,931 shares of the stock traded hands, compared to its average volume of 1,347,283. The business has a fifty day moving average of $247.59 and a 200-day moving average of $239.15. The firm has a market capitalization of $50.61 billion, a PE ratio of 37.12, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $263.70. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio (DPR) is currently 31.29%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Mizuho initiated coverage on shares of Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective for the company. Evercore ISI lifted their target price on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Wells Fargo & Company increased their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday. Finally, StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $280.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.